Image de couverture de livre

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Thomas A. Wadden, Maria A. Oquendo, Robert F. Kushner, Dachuang Cao, Chrisanthi A. Karanikas, Afton Kechter, Madhumita A. Murphy
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Obesity
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
par: Evgenia Gourgari, et autres
Publié: (2025)

Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4
par: Theresa Hunter Gibble, et autres
Publié: (2025)

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT ‐1 Over 176 Weeks
par: Hiddo J. L. Heerspink, et autres
Publié: (2026)

Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial
par: Yasushi Ishigaki, et autres
Publié: (2026)

Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials
par: Deborah B. Horn, et autres
Publié: (2025)

Response to “The safety of semaglutide in patients with depression and obesity”
par: Robert F. Kushner, et autres
Publié: (2024)

Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
par: Theresa Hunter Gibble, et autres
Publié: (2025)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
par: Alpana P. Shukla, et autres
Publié: (2025)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
par: Michelle Look, et autres
Publié: (2025)

Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
par: Beverly G. Tchang, et autres
Publié: (2025)

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment
par: Xuan Li, et autres
Publié: (2025)

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN
par: Deborah B. Horn, et autres
Publié: (2025)

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT ‐J Study
par: Hiroaki Masuzaki, et autres
Publié: (2026)

Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial
par: Lin Zhao, et autres
Publié: (2025)

Clarification of our response to “The importance of diversity in Obesity articles”
par: Michelle Cardel, et autres
Publié: (2024)

Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice
par: Hamlet Gasoyan, et autres
Publié: (2025)

Comment on ‘Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World ( STEER )’
par: Chih‐Yuan Wang
Publié: (2026)

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity
par: Andreea Ciudin, et autres
Publié: (2026)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
par: Domenica M. Rubino, et autres
Publié: (2025)

Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review
par: Geeta Pardeshi, et autres
Publié: (2025)

Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta‐Analysis
par: Jian‐Ying Wang, et autres
Publié: (2025)

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme
par: Brandon K. Bergman, et autres
Publié: (2025)

Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
par: Man Sun, et autres
Publié: (2026)

Six‐Month Real‐World Effectiveness, Persistence and Safety of Low‐to‐Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study
par: Nikolaos Angelopoulos, et autres
Publié: (2026)

Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults
par: Mai Katsura, et autres
Publié: (2026)

Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
par: A. B. M. Kamrul‐Hasan, et autres
Publié: (2024)

From Weight Loss to Multimorbidity Prevention: Framing the Anticipated Contributions of SURMOUNT ‐ MMO
par: Naveed Sattar
Publié: (2025)

Classification of Obesity Based on Weight History: Perceptions of People With Obesity
par: Bruno Halpern, et autres
Publié: (2026)

Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights
par: Emiliano G. Manueli Laos, et autres
Publié: (2026)

Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT‐CN study
par: Lin Zhao, et autres
Publié: (2025)

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison
par: Wojciech Michalak, et autres
Publié: (2026)

Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study
par: Jamy D. Ard, et autres
Publié: (2025)

Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study
par: Haiyan Cheng, et autres
Publié: (2026)

Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide
par: Sarah R. Barenbaum, et autres
Publié: (2026)

New Frontiers in Stand‐Alone Digital Obesity Treatment
par: Delia S. West, et autres
Publié: (2025)

New Drugs and Same Blind Spots—Rethinking Obesity Care in Later Life
par: John A. Batsis
Publié: (2025)

Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
par: Sharath Kommu, et autres
Publié: (2025)

Systematic Review of Loneliness and Social Isolation Interventions in Obesity and Obesity‐Related Complications
par: Ghada Alsultany, et autres
Publié: (2026)

Family Considerations in the Treatment of Adult Obesity With Antiobesity Medications
par: Keeley J. Pratt, et autres
Publié: (2025)

Gold and Clarke Questionnaires Identify Different People With Insulin‐Treated Diabetes and Impaired Awareness of Hypoglycaemia in Almost 60% of Cases: A Post Hoc Analysis From the Hypo‐ METRICS Study
par: Vaios Koutroukas, et autres
Publié: (2026)